A breakthrough approach to resolving this translational gap has now been pioneered by a research team led by Professor Sanguk Kim at POSTECH’s Department of Life Sciences and Graduate School of Artificial Intelligence. This multidisciplinary team, including Dr. Minhyuk Park, Mr. Woomin Song, and Mr. Hyunsoo Ahn, has developed an innovative machine learning framework that leverages biological differences between species to forecast drug toxicity more accurately in humans. Their findings, recently published in the prestigious journal eBioMedicine, set a new standard for preclinical drug safety evaluation by focusing on the fundamental genotype-phenotype disparities that exist between humans and experimental models.

At the core of this novel methodology is the concept of “Genotype-Phenotype Difference” (GPD)—the inherent biological variations between genomes and resulting phenotypes across species. Recognizing that genetic targets of drugs regulate cellular behavior differently in animal models compared to humans, the team constructed a predictive system that integrates three pivotal biological dimensions: gene essentiality, tissue-specific gene expression patterns, and gene network connectivity. Gene essentiality reflects the criticality of gene function for cell survival; tissue-specific expression profiles determine where and how genes operate within different biological contexts; and network connectivity maps the complexity of gene interactions that underpin functional pathways.

Empirical validation of the model was conducted on an extensive dataset encompassing 434 drugs flagged as hazardous and 790 drugs that successfully passed human trials. The results revealed a robust association between GPD attributes and clinical drug failure due to toxicity. Remarkably, the machine learning model demonstrated a substantial leap in predictive accuracy relative to traditional chemical structural analyses of drugs. Quantitatively, the model improved the area under the precision-recall curve (AUPRC) from 0.35 to 0.63 and achieved a receiver operating characteristic area under the curve (AUROC) of 0.75, compared to a near-chance 0.50 baseline for conventional approaches. This indicates a significant reduction in false positives and an enhanced ability to identify truly toxic therapeutics.

Beyond just retrospective assessment, the team put their AI framework to a stringent chronological validation test. By training the model exclusively on drug data available up to 1991, it successfully predicted, with 95% accuracy, drugs that were subsequently withdrawn from the market post-1991 due to unforeseen toxicity. This temporal robustness underscores the practical utility of the model in real-world drug surveillance and early safety screening, enabling pharmaceutical companies to flag at-risk candidates before costly and ethically fraught human trials commence.

This research marks a transformative step forward by scientifically quantifying and incorporating interspecies biological differences that have been largely overlooked or difficult to model within existing drug development pipelines. Traditionally, translational failures stem from oversimplified assumptions that animal model responses directly reflect human biology. However, the nuanced genotype-phenotype relationships encoded within each species’ genome influence cellular responses to pharmacological agents in a context-dependent manner, which this framework elucidates and harnesses to refine predictions of drug safety.

By adopting this GPD-centric approach, pharmaceutical research and development can realize multiple benefits. First, it promises to considerably diminish the pipeline attrition rate caused by late-stage toxicity, which is a major contributor to exorbitant costs, time delays, and ethical concerns in drug discovery. Second, it offers a mechanism to safeguard patients by preemptively identifying pharmaceuticals likely to cause harmful side effects upon human exposure. Third, as biological datasets continue to expand—spanning genomic annotations, transcriptomic profiles, and protein interaction networks—the predictive reliability and scope of this model are poised to grow exponentially.

Professor Sanguk Kim emphasized the pioneering nature of their work, noting, “This is the first attempt to incorporate differences in genotype-phenotype relationships for drug toxicity prediction. Our framework enables early identification of high-risk drugs in clinical development.” Co-first authors Dr. Minhyuk Park and Mr. Woomin Song echoed the practical impact: “The human-centered toxicity prediction model will be a very practical tool in new drug development. We anticipate that pharmaceutical companies will be able to screen out high-risk drugs in advance at the preclinical stage, thereby improving development efficiency.”

The strategic integration of advanced machine learning with deep biological insights represented by this study exemplifies the future direction of translational medicine and computational biology. Moving beyond purely chemical descriptors, this approach navigates the complex systems biology underlying drug responses across species, opening avenues towards more reliable and ethical drug discovery processes. Moreover, this method aligns with the overarching imperative of precision medicine—tailoring therapeutic strategies to the unique biological contexts of individual patients, beginning with a better understanding of species-specific genetic and phenotypic nuances.

Supported by the National Research Foundation of Korea, the Ministry of Science and ICT, the Medical Device Innovation Center, and the Synthetic Biology Human Resources Development Program, this research serves as a pioneering example of how interdisciplinary collaboration can accelerate medical innovation. By bridging the critical translational gap, this technology not only has the potential to revolutionize pharmaceutical pipelines worldwide but also offers hope for safer, more effective therapeutics that benefit patients globally.

As the pharmaceutical industry increasingly adopts such sophisticated machine learning tools, the hope is that catastrophic clinical trial failures will become a rarity rather than a distressing norm. Ultimately, this innovative framework underscores the vital role of understanding biological diversity and leveraging computational power, offering a paradigm shift in predicting drug toxicity and safeguarding human health.

Subject of Research: Drug toxicity prediction and genotype-phenotype differences between preclinical models and humans.

Article Title: Drug toxicity prediction based on genotype-phenotype differences between preclinical models and humans

News Publication Date: 28-Oct-2025

Web References: DOI Link

Image Credits: POSTECH

Keywords: Health and medicine, Drug therapy, Drug safety, Clinical medicine, Translational research, Translational medicine, Species interaction, Adaptive systems, Artificial intelligence, Deep learning, Computer science, Machine learning, Biological models, Animal models

In 2018, a transformative breakthrough came from the laboratory led by Jeffrey V. Ravetch at Rockefeller University. By engineering a novel CD40 agonist antibody named 2141-V11, his team introduced a molecule that not only exhibited enhanced efficacy but also exhibited a safety profile enabling more strategic administration routes. This antibody was uniquely modified to engage specific Fc receptors, which amplified its ability to crosslink and activate immune cells critical to antitumor responses, significantly boosting its functional potency compared to previous antibodies. The initial evidence supporting this innovation stemmed from sophisticated mouse models genetically engineered to recapitulate human immune pathways, underscoring their predictive relevance.

Building upon these preclinical foundations, the crucial next step was to subject 2141-V11 to rigorous clinical evaluation. Recently, the outcomes of a phase 1 trial involving a cohort of 12 patients afflicted with various metastatic cancers were disclosed in the journal Cancer Cell. Astonishingly, half the patients exhibited objective tumor shrinkage, with two achieving complete remission, a rare and encouraging outcome in such early-stage trials. These results provide a glimpse at an immunotherapy capable of generating robust systemic antitumor immune responses following local administration.

What makes 2141-V11 particularly revolutionary is its mode of delivery. Unlike previous CD40 antibodies given intravenously, 2141-V11 was injected directly into tumors. This localized delivery method sharply reduces exposure to healthy tissues rich in CD40 receptors, helping to mitigate systemic toxicity—a major limitation of earlier therapies. Accordingly, the patients experienced only mild side effects, a stark contrast to the significant toxicities historically tied to this drug class. This innovative administration not only preserved safety but also triggered systemic immune activation, with distant, non-injected tumors undergoing regression or complete destruction as immune cells homed to these sites.

At a molecular level, CD40 functions as a crucial receptor expressed predominantly on antigen-presenting cells like dendritic cells and B cells. Its activation is a linchpin for initiating a cascade of immune signals that prime cytotoxic T cells to recognize and eliminate tumor cells. However, achieving potent CD40 engagement without widespread receptor activation in non-target tissues has been a long-standing challenge. The engineering of 2141-V11 overcame this hurdle by optimizing the antibody’s Fc region, facilitating enhanced crosslinking that is selectively augmented in the tumor microenvironment, precisely where immune activation is needed most.

Histological examination of tumor biopsies from injected sites revealed a remarkable transformation of the tumor microenvironment. The presence of dense infiltrates composed of varied immune cells, including dendritic cells, mature B cells, and multiple T cell subsets, was observed. These immune cells organized into highly structured lymphoid aggregates termed tertiary lymphoid structures (TLS). TLS resemble lymph nodes and represent specialized sites for local immune priming and activation. The formation of TLS within tumors is widely associated with better prognosis and responsiveness to immunotherapies, suggesting that 2141-V11 effectively “reprograms” the tumor niche into an immune-reactive hub.

Even more compelling was the observation that TLS formation extended beyond the directly injected tumors. The systemic immune stimulation induced by 2141-V11 led to immune cell migration and TLS establishment at distant tumor sites, offering an explanation for the systemic tumor regressions noted in the clinical trial. This systemic effect following localized therapy sets 2141-V11 apart from many immunotherapeutic agents, highlighting a novel avenue for inducing robust, body-wide antitumor immunity with minimized systemic toxicity.

The phase 1 trial encompassed a diverse group of patients with metastatic melanoma, renal cell carcinoma, and various breast cancer subtypes, all typically resistant to conventional therapies. Among these, the two complete responders had notoriously aggressive diseases, making their outcomes especially noteworthy. One melanoma patient with numerous metastatic lesions experienced complete disappearance of uninjected tumors following localized treatment of a single site. The breast cancer patient displayed a similar pattern of widespread tumor clearance after a single tumor injection. These extraordinary results underline the transformative potential of 2141-V11 for difficult-to-treat, metastatic cancers.

Importantly, researchers are now investigating why some patients respond spectacularly while others do not. Initial analyses implicated T cell clonality as a key biomarker; patients with a high diversity and abundance of tumor-reactive T cells prior to treatment appeared more likely to benefit from 2141-V11. Understanding these immune parameters will be critical to refining patient selection and personalizing therapeutic strategies, potentially enhancing response rates beyond the current immunotherapy benchmark of 25 to 30 percent.

Building on this promise, several ongoing clinical trials spearheaded by the Ravetch laboratory in collaboration with Memorial Sloan Kettering and Duke University are evaluating 2141-V11 in other challenging malignancies, including bladder cancer, prostate cancer, and glioblastoma, cancers known for their aggressive nature and resistance to standard treatments. These phase 1 and 2 studies collectively enroll nearly 200 patients, aiming to unravel the mechanisms of action, optimize dosing, and expand therapeutic indications.

The era of Fc-engineered immunomodulatory antibodies heralds a paradigm shift in cancer therapy. By harnessing nuanced antibody engineering and adaptive delivery techniques, compounds like 2141-V11 transcend prior limitations, offering renewed hope for effective, systemic antitumor immunity with manageable safety profiles. While many hurdles remain—including comprehensive biomarker discovery and combination therapy optimization—these findings mark a significant milestone in realizing the full promise of CD40-targeted immunotherapy.

As the oncology community continues to dissect the complex interactions within the tumor microenvironment and systemic immune networks, the success of 2141-V11 provides a blueprint for next-generation immune agonists. Decoding why some immune systems mount vigorous responses while others falter will be paramount in converting the majority of cancer patients into responders. This knowledge could revolutionize not only CD40 agonists but the broader field of immune-based cancer therapies, influencing clinical decision-making and ushering in more durable, efficacious treatments.

Ultimately, the story of 2141-V11 exemplifies the power of translational research, from molecular engineering in the lab to tangible patient benefit. As additional trials unfold and our understanding deepens, this Fc-optimized CD40 agonistic antibody stands poised to redefine the therapeutic landscape, offering renewed hope to patients battling metastatic cancers worldwide.

Subject of Research: Fc-engineered CD40 agonist antibodies for cancer immunotherapy and their clinical evaluation in metastatic cancers.

Article Title: Fc-optimized CD40 Agonistic Antibody Elicits Tertiary Lymphoid Structure Formation and Systemic Antitumor Immunity in Metastatic Cancer

News Publication Date: 14-Aug-2025

Web References:
https://www.pnas.org/doi/10.1073/pnas.1810566115
http://dx.doi.org/10.1016/j.ccell.2025.07.013

Keywords: Cancer immunotherapy, Clinical trials, CD40 agonist antibody, Fc engineering, Tertiary lymphoid structures, Metastatic cancer, Immuno-oncology